BIOLASE ( NASDAQ:BIOL – Get Rating ) ‘s stock had its 'speculative buy' rating restated by equities researchers at Benchmark in a research report issued on Wednesday, Benzinga reports. They presently have a $2.00 price target on the medical technology company's stock. Benchmark's target price would indicate a potential upside of 496.48% from the stock's current price. Other equities analysts have also issued research reports about the company. Lake Street Capital reiterated a 'buy' rating on shares of BIOLASE in a research note on Friday, January 20th.

https://www.dailypolitical.com/2023/03/29/biolase-nasdaqbiol-given-speculative-buy-rating-at-benchmark.html

#dailypolitical